The goal of this Phase 3 clinical trial is to test how safe and effective Belantamab Mafodotin is in the treatment of relapsed/refractory myeloma. One group of patients will receive Belantamab Mafodotin, and the other will receive Pomalidomide + low dose Dexamethasone. Researchers will compare the two groups of patients to help them understand how well Belantamab Mafodotin works when compared to Pomalidomide + Dexamethasone.
This trial is currently open and accepting patients.
This trial is seeking approximately 320 patients, and organized into two separate groups, called arms. This trial is randomized, which means patient will be randomly assigned into their group. This trial is open label, which means that both the patients and doctors will know which group they have been assigned to, and which drugs they will be receiving.
Patients will receive the study drugs until they decide to stop participating, their myeloma gets worse, they develop bad side effects, die, or the study ends. If you stop participating in the study and your myeloma has not gotten worse, you will be asked to participate in follow up visits every 3 weeks. If you stop participating in the study and your myeloma has gotten worse, you will be asked to participate in a phone or email follow-up communication every 3 months until the end of the study.
Enrollment: 320 patients (estimated)View More
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.
View all clinical trial locations sorted by state.
Santa Barbara, CA
Lake Success, NY
Deer Park, OH
Read the latest news and updates on this trial.
July 14, 2020
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to 0 in favor of approving belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have previously received at least 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and a CD38-directed antibody.
January 21, 2020
March 21, 2019
Median progression-free survival extends to twelve months
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message